GlassScriptPhysician profile
Samuel Bair
NPI 1497435093
$1,352.42
in general payments reported to CMS, 2019-2025
18 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $99.15 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $313.78 | 2024-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $169.78 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $136.66 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $136.44 | 2025 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $130.20 | 2024-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $108.08 | 2025 | |
| Shield Therapeutics INC | $62.45 | 2025 | |
| Mayne Pharma Commercial LLC | $49.52 | 2025 | |
| Sumitomo Pharma America, INC. | $45.59 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $35.87 | 2025 | Arexvy, Shingrix |
| Sun Pharmaceutical Industries INC. | $33.01 | 2025 | |
| Medicomp INC | $20.81 | 2025 | Telepatch Cardiac Monitor |
| Pfizer INC. | $20.26 | 2025 | |
| Idorsia Pharmaceuticals US INC | $19.31 | 2025 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Uptravi, Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.72 | 2025 | |
| Convatec INC. | $17.28 | 2024 | |
| Amgen INC. | $16.61 | 2025 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.